Understanding how DNA damage affects testicular cancer treatment.
The role of the DNA damage response in the development and therapeutic sensitivity of malignant testicular germ cell tumors.
This study is looking at how testicular germ cell tumors handle DNA damage differently than other cancers, which might help explain why they respond so well to chemotherapy, and the goal is to find ways to use this information to create better treatments for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-11003748 on NIH RePORTER |
What this research studies
This research investigates the unique way testicular germ cell tumors (TGCTs) respond to DNA damage, which may explain their high sensitivity to chemotherapy. By using a specially designed mouse model, researchers will explore how these tumors differ from other cancers in their DNA damage response mechanisms. The study aims to uncover the biological processes that allow TGCTs to avoid genetic alterations and how these processes can be leveraged to improve treatment outcomes for patients. Patients may benefit from insights that could lead to more effective therapies tailored to their specific tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with testicular germ cell tumors who are undergoing or have undergone chemotherapy.
Not a fit: Patients with other types of cancers or those who do not have testicular germ cell tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for testicular cancer, enhancing patient outcomes.
How similar studies have performed: Previous research has shown that understanding DNA damage responses in cancer can lead to significant advancements in treatment, suggesting this approach has potential for success.
Where this research is happening
Ithaca, United States
- Cornell University — Ithaca, United States (Active)
Researchers
- Principal investigator: Loehr, Amanda — Cornell University
- Study coordinator: Loehr, Amanda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.